Adma Biologics reported $55.44M in EBITDA for its fiscal quarter ending in June of 2026.





Ebitda Change Date
Adma Biologics USD 55.44M 5.62M Jun/2026
Alnylam Pharmaceuticals USD 360.27M 114.93M Sep/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Novavax USD 19.36M 190.79M Dec/2025
Omeros USD -47.96M 7.39M Sep/2023
Takeda JPY 369.75B 5.29B Sep/2026